Ectoparasites and fitness

Excel spreadsheets of data on 1) ectoparasite manipulation on female fitness and 2) treatment vs female parasite loads. The data were collected under natural conditions in the field

Flow chart of the study population.

<p>Flow chart of the study population.</p

Univariable logistic regression analyses of long-term mortality for sociodemographic, clinical, and Health-related Quality of Life Data (HRQOL) Data.

<p>OR = Odds ratio; CI = Confidence interval; p = p-value; ASA = American Society of Anesthesiologists.</p>**<p>Measured by the Physiological and Operative Severity Scoring system for enUmeration of Mortality and morbidity (POSSUM) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0085456#pone.0085456-Copeland1" target="_blank">[28]</a>.</p>***<p>EORTC QLQ-C30 Questionnaire; Continuous range;</p><p>³High scores represent better function;</p>4<p>High score represent worse symptoms.</p

Changing of symptom related Health Related Quality of life–domains from preoperative baseline to 12 months follow up.

<p>The mean scores of the EORTC QLQ-C30 symptoms domains for survivors, non-survivors (data baseline and follow up after 3 months) and the reference values for women and men for the same-aged German population are shown. Higher scores represent higher symptom burden. The burden of appetite loss in the baseline was significant higher in non-survivors (p = 0.008) whereas the remaining symptom scales were not significant different between both groups in baseline assessment. The symptom burden increased in all domains 3 months after surgery. In survivors, one year after surgery, appetite loss and nausea and vomiting were similar to baseline levels, whereas fatigue (p<0.001), pain (p = 0.015), dyspnea (p<0.001), and financial difficulties (p = 0.001) were worse compared to baseline but improved in comparison to the 3 months follow up. The increase in symptom burden was moderate (10–20 points increase).</p

Patients characteristic – Sociodemographic and clinical variables, stratified for Non-Survivors/Survivors.

<p>²Mann – Whitney –U-Test,</p><p>³Χ² test,</p>4<p>Cochran-Armitage trend test;</p>**<p>Measured by the Physiological and Operative Severity Scoring system for enUmeration of Mortality and morbidity (POSSUM) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0085456#pone.0085456-Copeland1" target="_blank">[28]</a>.</p><p>SD: standard deviation, IQR: interquartile range, BMI: body mass index, GDS: geriatric depression scale; GI: Gastrointestinal, ASA: American Society of Anesthesiologists.</p

Comparison of port duration between interventionally and surgically implanted devices

<p><b>Copyright information:</b></p><p>Taken from "Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: A phase II-study and historical comparison with the surgical approach"</p><p>http://www.biomedcentral.com/1471-2407/7/69</p><p>BMC Cancer 2007;7():69-69.</p><p>Published online 24 Apr 2007</p><p>PMCID:PMC1871598.</p><p></p

Published studies on the frequency of the MSI or MMR-defective phenotype in Pancreatic Ductal Adenocarcinoma.

*<p>Tumor specimens passed through xeno-transplantation of PDAC, unspecified whether consecutively collected.</p>#<p>By genomic DNA analysis for mutations.</p>§<p>Medullary cancers selected out of 450 randomly chosen PDAC.</p><p>“One patient with positive Bethesda criteria but negative <i>hMLH1</i> mutational analysis.</p><p>°3 PDAC arising in LS patients added to a series of 100 patients, unspecified whether consecutive.</p>∧<p>Long survivors (≥3 years) selected out of 373 PDAC patients.</p

Sequences of the primers employed for <i>BRAF^V600E</i> analysis.

<p>Sequences of the primers employed for <i>BRAF^V600E</i> analysis.</p

Patient demographics and survival, family history of gastrointestinal cancer, tumor pathological and molecular features, in 338 consecutively resected PDAC.

*<p>Including stomach, colon and pancreatic cancer in first degree relatives.</p><p>°Reported as G4 with respect to Tumor Grade.</p

Table_1_Feasibility and Efficacy of Adjuvant Chemotherapy With Gemcitabine After Liver Transplantation for Perihilar Cholangiocarcinoma - A Multi-Center, Randomized, Controlled Trial (pro-duct001).docx

BackgroundLiver transplantation (LT) is considered a therapeutic option for unresectable perihilar cholangiocarcinoma (PHC) within defined criteria. It remains uncertain whether patients can safely receive adjuvant chemotherapy after LT.MethodsWe performed a prospective, multi-center, randomized, non-blinded two-arm trial (pro-duct001). Patients after LT for unresectable PHC within defined criteria were randomized to adjuvant gemcitabine (LT-Gem group) and LT alone (LT alone group). The primary objective was to investigate if adjuvant chemotherapy is feasible in ≥ 85% of patients after LT. The primary endpoint was the percentage of patients completing the 24 weeks course of adjuvant chemotherapy. Secondary endpoints included overall survival (OS) and disease-free (DFS), and complication rates.ResultsTwelve patients underwent LT for PHC, of which six (50%) were eligible for randomization (LT-Gem: three patients, LT alone: three patients). Two out of three patients discontinued adjuvant chemotherapy after LT due to intolerance. The study was prematurely terminated due to slow enrollment. One patient with PHC had underlying primary sclerosing cholangitis (PSC). Tumor-free margins could be achieved in all patients. In both the LT-Gem and the LT alone group, the cumulative 1-, 3-, and 5-year OS and DFS rates were 100%, 100%, 67%, and 100%, 67% and 67%, respectively.ConclusionsThis prospective, multi-center study was prematurely terminated due to slow enrollment and a statement on the defined endpoints cannot be made. Nevertheless, long-term survival data are consistent with available retrospective data and confirm defined criteria for LT. Since more evidence of LT per se in unresectable PHC is urgently needed, a prospective, non-randomized follow-up study (pro-duct002) has since been launched.</p